



Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024

July 11, 2024

SAN DIEGO--(BUSINESS WIRE)--Jul. 11, 2024-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results.

A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at <http://investor.tandemdiabetes.com> in the "Events & Presentations" section. To access the call by phone, please use this link (<https://register.vevent.com/register/B1c1efe0f41c4149d2ae27551b0212f1cf>) and you will be provided with dial-in details, including a personal pin.

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care's Investor Center website located at <http://investor.tandemdiabetes.com> in the "Events & Presentations" section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240711833057/en/): <https://www.businesswire.com/news/home/20240711833057/en/>

Media Contact:

858-366-6900

media@tandemdiabetes.com

Investor Contact:

858-366-6900

IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.